Literature DB >> 18242200

FDA approves sorafenib for patients with inoperable liver cancer.

Les Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18242200     DOI： 10.1053/j.gastro.2007.12.037

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  48 in total

Review 1.  Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

Authors:  Laura E MacConaill; Paul Van Hummelen; Matthew Meyerson; William C Hahn
Journal:  Cancer Discov       Date:  2011-09       Impact factor: 39.397

2.  TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

Authors:  Bruno-Christian Koehler; Toni Urbanik; Binje Vick; Regina-Johanna Boger; Steffen Heeger; Peter-R Galle; Marcus Schuchmann; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

3.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 4.  Metabolic targets for potential prostate cancer therapeutics.

Authors:  Jeffrey Twum-Ampofo; De-Xue Fu; Antonino Passaniti; Arif Hussain; M Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

5.  Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Authors:  Jessie Torgersen; Tamar H Taddei; Lesley S Park; Dena M Carbonari; Michael J Kallan; Kisha Mitchell Richards; Xuchen Zhang; Darshana Jhala; Norbert Bräu; Robert Homer; Kathryn D'Addeo; Rajni Mehta; Melissa Skanderson; Farah Kidwai-Khan; Amy C Justice; Vincent Lo Re
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10-01       Impact factor: 4.254

6.  Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).

Authors:  Zeeshan Butt; Neehar D Parikh; Jennifer L Beaumont; Sarah K Rosenbloom; Karen L Syrjala; Amy P Abernethy; Al B Benson; David Cella
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

7.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Authors:  Pippa Newell; Sara Toffanin; Augusto Villanueva; Derek Y Chiang; Beatriz Minguez; Laia Cabellos; Radoslav Savic; Yujin Hoshida; Kiat Hon Lim; Pedro Melgar-Lesmes; Steven Yea; Judit Peix; Kemal Deniz; M Isabel Fiel; Swan Thung; Clara Alsinet; Victoria Tovar; Vincenzo Mazzaferro; Jordi Bruix; Sasan Roayaie; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  J Hepatol       Date:  2009-06-12       Impact factor: 25.083

8.  Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Authors:  Mhd Yaser Al-Marrawi; Bikramajit Singh Saroya; Matthew C Brennan; Zhaohai Yang; Thomas M Dykes; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2013-06-13       Impact factor: 4.742

9.  Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.

Authors:  Jung-Min Lee; Christina M Annunziata; John L Hays; Liang Cao; Peter Choyke; Minshu Yu; Daniel An; Ismail Baris Turkbey; Lori M Minasian; Seth M Steinberg; Helen Chen; John Wright; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2020-08-01       Impact factor: 5.482

10.  Psychometric properties of a brief, clinically relevant measure of pain in patients with hepatocellular carcinoma.

Authors:  Zeeshan Butt; Jin-Shei Lai; Jennifer L Beaumont; Karen Kaiser; Rajiv Mallick; David Cella; Jennifer L Steel
Journal:  Qual Life Res       Date:  2014-04-20       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.